Vitamin C Inhibits Angiotensin-Converting Enzyme-2 in Isolated Rat Aortic Ring.

Q2 Medicine

Cardiovascular and Hematological Disorders - Drug Targets Pub Date : 2021-01-01 DOI:10.2174/1871529X21666211214153308

Ayoub Amssayef, Ismail Bouadid, Mohamed Eddouks

{"title":"Vitamin C Inhibits Angiotensin-Converting Enzyme-2 in Isolated Rat Aortic Ring.","authors":"Ayoub Amssayef, Ismail Bouadid, Mohamed Eddouks","doi":"10.2174/1871529X21666211214153308","DOIUrl":null,"url":null,"abstract":"Aims: The study aimed to assess the inhibitory effect of Vitamin C on angiotensin-converting enzyme 2.Background: Coronavirus disease 2019 (COVID-19) is a disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which uses angiotensin-converting enzyme 2 (ACE-II) as the first route to infect human cells. Accordingly, agents with potential inhibition of ACE-II receptors might be effective in the prevention and management of COVID-19.Objective: The goal of this work was to assess the possible inhibitory effect of ACE-II on ascorbic acid using an ex vivo approach based on the inhibition of diminazene-induced vasorelaxation.Materials and methods: In the present study, diminazene was used as a known specific inhibitor of ACE-II. Then, the vasorelaxant effect of ascorbic acid on diminazene-induced relaxation was examined using isolated aortic rings. All experiments of this study were evaluated on isolated aortic rings precontracted by epinephrine.Results: The results confirmed that diminazene-induced vasorelaxation in a dose-dependent manner. More interestingly, ascorbic acid inhibited diminazene-induced vasorelaxation in a dose-dependent manner.Conclusion: This investigation provides valuable experimental proof of the efficacy of ascorbic acid (Vitamin C) on inhibiting ex vivo vascular angiotensin-converting enzyme II, which is known among the pharmacological targets of anti-COVID-19 drugs.","PeriodicalId":9543,"journal":{"name":"Cardiovascular and Hematological Disorders - Drug Targets","volume":"21 4","pages":"235-242"},"PeriodicalIF":0.0000,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cardiovascular and Hematological Disorders - Drug Targets","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1871529X21666211214153308","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Aims: The study aimed to assess the inhibitory effect of Vitamin C on angiotensin-converting enzyme 2.

Background: Coronavirus disease 2019 (COVID-19) is a disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which uses angiotensin-converting enzyme 2 (ACE-II) as the first route to infect human cells. Accordingly, agents with potential inhibition of ACE-II receptors might be effective in the prevention and management of COVID-19.

Objective: The goal of this work was to assess the possible inhibitory effect of ACE-II on ascorbic acid using an ex vivo approach based on the inhibition of diminazene-induced vasorelaxation.

Materials and methods: In the present study, diminazene was used as a known specific inhibitor of ACE-II. Then, the vasorelaxant effect of ascorbic acid on diminazene-induced relaxation was examined using isolated aortic rings. All experiments of this study were evaluated on isolated aortic rings precontracted by epinephrine.

Results: The results confirmed that diminazene-induced vasorelaxation in a dose-dependent manner. More interestingly, ascorbic acid inhibited diminazene-induced vasorelaxation in a dose-dependent manner.

Conclusion: This investigation provides valuable experimental proof of the efficacy of ascorbic acid (Vitamin C) on inhibiting ex vivo vascular angiotensin-converting enzyme II, which is known among the pharmacological targets of anti-COVID-19 drugs.

查看原文本刊更多论文

维生素C抑制离体大鼠主动脉环血管紧张素转换酶-2

目的:研究维生素C对血管紧张素转换酶2的抑制作用。背景:冠状病毒病2019 (COVID-19)是一种由严重急性呼吸综合征冠状病毒2型(SARS-CoV-2)引起的疾病，它以血管紧张素转换酶2 (ACE-II)为感染人类细胞的第一途径。因此，对ACE-II受体具有潜在抑制作用的药物可能在COVID-19的预防和管理中有效。目的:本研究的目的是利用体外方法评估ACE-II对抗坏血酸的可能抑制作用，该方法基于对咪纳苯诱导的血管松弛的抑制。材料和方法:在本研究中，咪纳烯被用作已知的ACE-II特异性抑制剂。然后，用离体主动脉环观察抗坏血酸对氨基萘诱导的血管松弛的作用。本研究的所有实验都是在肾上腺素预收缩的离体主动脉环上进行的。结果:证实了地那芬诱导的血管舒张呈剂量依赖性。更有趣的是，抗坏血酸以剂量依赖的方式抑制了氨基萘诱导的血管松弛。结论:本研究为抗坏血酸(维生素C)抑制体外血管紧张素转换酶II的作用提供了有价值的实验证据，这是已知的抗covid -19药物的药理靶点之一。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cardiovascular and Hematological Disorders - Drug Targets Medicine-Cardiology and Cardiovascular Medicine

CiteScore

1.90

自引率

0.00%

发文量

期刊介绍： Cardiovascular & Hematological Disorders - Drug Targets aims to cover all the latest and outstanding developments on the medicinal chemistry, pharmacology, molecular biology, genomics and biochemistry of contemporary molecular targets involved in cardiovascular and hematological disorders e.g. disease specific proteins, receptors, enzymes, genes. Each issue of the journal contains a series of timely in-depth reviews written by leaders in the field covering a range of current topics on drug targets involved in cardiovascular and hematological disorders. As the discovery, identification, characterization and validation of novel human drug targets for cardiovascular and hematological drug discovery continues to grow.